Our Krabbe disease community received some disappointing news today. PassageBio will stop further clinical development of PBKR03 for Krabbe disease.
“There’s no doubt this news is upsetting but we won’t allow it to disrupt our momentum in achieving advances in research and patient care for those impacted by Krabbe disease. However, I do yearn for the right company to utilize the research and work conducted under Passage Bio for PBKR03 to bring the treatment to the finish line. We will have to wait and see if that’s in the cards. To all of the families and patients, tough news and disappointing results are part of the path in all rare diseases. We must stay the course and stay focused because that’s how we will #curekrabbe.” – Stacy Pike-Langenfeld, President, KrabbeConnect